OCEAN Study for EGPA
Trial Objectives
People with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications: mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year. Researchers want to understand if depemokimab is as safe and effective as mepolizumab. Volunteers will receive a blood draw and will be randomly assigned to receive an injection of one of the two medications.